ITP Publications

References

1. Thrombopoietin (TPO) receptor agonists for the treatment of immune thrombocytopenia (ITP).
   Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186. [Full Text]
2. The role of rituximab in the treatment of immune thrombocytopenia (ITP).
   Godeau B, Porcher R, Fain O, Lefrere F, Fenaux P, Cheze S, Vekhoff A, Chauveheid MP, Stirnemann J, Galicier L, Bourgeois E, Roudot-Thoraval F, Khellaf M, Michel M, Schaeffer A, Moulis G, Germain JF, Hulin C, Desforges L, Guillemin F, Hatron PY, Papo T, Lafon I, Kahn JE, Piette AM, Morinet F, Michel C, Quemeneur T, Salmon D, Hunault M, Perez M, Lefebvre JM, Zver S, Ghesquieres H, Chauvelot-Moachon L, Bierling P, Viallard JF, Perez C, Gyan E, Hamidou M, Cornet Y, Genet P, Socie G; French Study Group on ITP. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999-1004. [Full Text]
3. Long-term complications and sequelae of immune thrombocytopenia (ITP) and its treatments.
   Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25-33. [Full Text]
4. Management of acute immune thrombocytopenia (ITP) in adults.
   Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207. [Full Text]
5. Management of chronic immune thrombocytopenia (ITP) in adults.
   Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse A, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong R, Young J, Zaja F, Kuter DJ. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817. [Full Text]
6. Management of pediatric immune thrombocytopenia (ITP).
   Neunert CE, Buchanan GR, Imbach P, Bolton-Maggs PH, Bennett CM, Neufeld EJ, Vesely SK, Adix L, Blanchette VS, Kühne T. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood. 2008;112(10):4003-4008. [Full Text]
7. Management of immune thrombocytopenia (ITP) in adults without bleeding.
   British Committee for Standards in Haematology, Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse A, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong R, Young J, Zaja F, Kuter DJ. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817. [Full Text]
8. Management of immune thrombocytopenia (ITP) in children.
   Kühne T, Buchanan GR, Zimmerman S, Michaels LA, Kohan R, Berchtold W, Imbach P; Intercontinental Childhood ITP Study Group. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr. 2003;143(5):605-608. [Full Text]